Online first
Original article
Published online: 2025-03-13
Cardiac pacemakers and implantable cardioverter-defibrillators without cardiac resynchronization capability: Impact on cardiac function in a median follow-up of 1-year
Pubmed: 40079711
Abstract
Not available
References
- Glikson M, Nielsen JC, Kronborg MB, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42(35): 3427–3520.
- Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
- Chang JD, Manning WJ, Ebrille E, et al. Tricuspid valve dysfunction following pacemaker or cardioverter-defibrillator implantation. J Am Coll Cardiol. 2017; 69(18): 2331–2341.
- Mizner J, Waldauf P, Grieco D, et al. A randomized comparison of HBP versus RVP: Effect on left ventricular function and biomarkers of collagen metabolism. Kardiol Pol. 2023; 81(5): 472–481.
- Matusik PT, Prior SM, Butenas S, et al. Association of cardiac troponin I with prothrombotic alterations in atrial fibrillation. Kardiol Pol. 2018; 76(7): 1106–1109.
- Borowiec K, Woźniak O, Wróbel A, et al. A new model for predicting adverse outcomes in arrhythmogenic right ventricular cardiomyopathy. Pol Arch Intern Med. 2023; 133(7-8): 16443.
- Ooka J, Tanaka H, Hatani Y, et al. Risk stratification of future left ventricular dysfunction for patients with indications for right ventricular pacing due to bradycardia. Int Heart J. 2017; 58(5): 724–730.
- Stanek A, Lelakowski J, Matusik PT. Cardiac remodelling and function after cardiovascular implantable electronic devices implantation [article in Polish]. Pol Merkur Lekarski. 2019; 46(274): 187–189.
- Matusik PT. Adverse clinical outcomes related to right ventricular pacing. Eur Heart J. 2019; 40(20): 1586–1588.
- Khurshid S, Epstein AE, Verdino RJ, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014; 11(9): 1619–1625.
- Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. 2021; 60(4): 727–800.
- Kaye G, Ng JY, Ahmed S, et al. The prevalence of pacing-induced cardiomyopathy (PICM) in patients with long term right ventricular pacing - is it a matter of definition? Heart Lung Circ. 2019; 28(7): 1027–1033.
- Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023; 20(9): e17–e91.
- Chung CTo, Bazoukis G, Radford D, et al. Predictive risk models for forecasting arrhythmic outcomes in Brugada syndrome: A focused review. J Electrocardiol. 2022; 72: 28–34.
- Matusik PS, Bryll A, Matusik PT, et al. Electrocardiography and cardiac magnetic resonance imaging in the detection of left ventricular hypertrophy: The impact of indexing methods. Kardiol Pol. 2020; 78(9): 889–898.
- Matusik PT, Heleniak Z, Papuga-Szela E, et al. Chronic kidney disease and its impact on a prothrombotic state in patients with atrial fibrillation. J Clin Med. 2020; 9(8): 2476.
- Traykov V, Dzhinsov K, Matusik PT. Infections of cardiac implantable electronic devices: Epidemiology, mechanisms, and preventive measures. Kardiol Pol. 2023; 81(9): 859–869.
- Kachboura S, Ben Halima A, Fersi I, et al. Assessment of heart failure and left ventricular systolic dysfunction after cardiac pacing in patients with preserved left ventricular systolic function. Ann Cardiol Angeiol (Paris). 2008; 57(1): 29–36.
- Xin MK, Gao P, Zhang SY. Effects of long-term right ventricular apex pacing on left ventricular dyssynchrony, morphology and systolic function. Int J Cardiol. 2021; 331: 91–99.
- Tatum R, Maynes EJ, Wood CT, et al. Tricuspid regurgitation associated with implantable electrical device insertion: A systematic review and meta-analysis. Pacing Clin Electrophysiol. 2021; 44(8): 1297–1302.
- Chodór-Rozwadowska K, Sawicka M, Morawski S, et al. Impact of lead position on tricuspid regurgitation, ventricular function, and heart failure exacerbation and mortality after cardiac implantable electronic device implantation. Preliminary results from the PACE-RVTR Registry. Kardiol Pol. 2024; 82(1): 53–62.
- Sadreddini M, Haroun MJ, Buikema L, et al. Tricuspid valve regurgitation following temporary or permanent endocardial lead insertion, and the impact of cardiac resynchronization therapy. Open Cardiovasc Med J. 2014; 8: 113–120.
- Riesenhuber M, Spannbauer A, Gwechenberger M, et al. Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation. Clin Res Cardiol. 2021; 110(6): 884–894.
- Nazmul MN, Cha YM, Lin G, et al. Percutaneous pacemaker or implantable cardioverter-defibrillator lead removal in an attempt to improve symptomatic tricuspid regurgitation. Europace. 2013; 15(3): 409–413.
- Vijayaraman P, Chung MK, Dandamudi G, et al. His Bundle Pacing. J Am Coll Cardiol. 2018; 72(8): 927–947.
- Matusik PT, Szotek M, Komar M, et al. His bundle pacing in a patient with complete atrioventricular block and congenitally corrected transposition of the great arteries: potential of the use of extended reality and cardiac electrical activity projected into a 3-dimensional heart model. Pol Arch Intern Med. 2025; 135(1): 16856.
- Tjong FVY, Reddy VY. Permanent leadless cardiac pacemaker therapy: a comprehensive review. Circulation. 2017; 135(15): 1458–1470.
- Rutzen-Lopez H, Silva J, Helm RH. Leadless cardiac devices-pacemakers and implantable cardioverter-defibrillators. Curr Treat Options Cardiovasc Med. 2016; 18(8): 49.
- Savarimuthu S, Roy S, Obeidat M, et al. Subcutaneous implantable cardioverter defibrillator: Can it overtake its transvenous counterpart. Pacing Clin Electrophysiol. 2021; 44(8): 1413–1420.
